Details

Indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.

type

FDA Approval

approval date

2022-03-24

settings
settings
Castration-resistant
settings
Metastatic
settings
Subsequent line
source

FDA